Article - 27/06/2011 The EURAT project at the Marsilius Kolleg in Heidelberg Bioinformaticians, human geneticists, molecular biologists, oncologists, pathologists, lawyers and theologians are all participating in the project “Ethical and legal aspects of the total sequencing of the human genome” (EURAT) being carried out at Heidelberg University’s Marsilius Kolleg. The project partners are developing a common viewpoint and working out solutions for problems arising from the possibilities of total genome sequencing. https://www.gesundheitsindustrie-bw.de/en/article/news/the-eurat-project-at-the-marsilius-kolleg-in-heidelberg
Press release - 27/06/2011 NMI TT GmbH – creating value from research NMI TT GmbH is a subsidiary of the NMI Natural and Medical Sciences Institute in Reutlingen with which it works closely. Developments by the renowned NMI are commercialised by NMI TT GmbH and the profit flows back into the NMI’s research activities – thus leading to a value creation cycle that benefits research and development as well as the economy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmi-tt-gmbh-creating-value-from-research
Press release - 25/06/2011 Researching the senses: University of Hohenheim among Europe’s top universities Scents that lead insects by the nose, olfactory cells in the intestines, and the basic principles of the sense of smell are topics that have catapulted Prof. Dr. Breer from the University of Hohenheim into the top ranks of European scientists working on research into the senses. The journal Lab Times has ranked Breer one of the most frequently cited German scientists in European ear, nose and throat research.https://www.gesundheitsindustrie-bw.de/en/article/press-release/researching-the-senses-university-of-hohenheim-among-europe-s-top-universities
Press release - 22/06/2011 SYGNIS Pharma AG secures further financial resources with shareholder loan SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today executed a subordinated loan agreement for a total amount of EUR 6 million with its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany (dievini), with an interest-rate at customary market conditions. As a result this loan, which is payable on demand, secures the financing of SYGNIS’ existing operations, according to the present plans, at…https://www.gesundheitsindustrie-bw.de/en/article/press-release/sygnis-pharma-ag-secures-further-financial-resources-with-shareholder-loan
Article - 20/06/2011 Molecular biologists to celebrate 50th anniversary of Jacob and Monod’s operon model Leading molecular biologists from around the world came together at a conference jointly organized by the European Molecular Biology Organisation (EMBO) and the Institut Pasteur in Paris between 17th and 20th May to celebrate the 50th anniversary of the operon concept published by François Jacob and Jacques Monod in 1961. The scientists discussed concepts and research results influenced by the operon model, which have led to our present…https://www.gesundheitsindustrie-bw.de/en/article/news/molecular-biologists-to-celebrate-50th-anniversary-of-jacob-and-monod-s-operon-model
Press release - 20/06/2011 CureVac presents new data for prostate and lung cancer vaccines CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
Article - 20/06/2011 How plants change their shape – researchers at KIT investigate cytoskeletal processes Organisms have two possibilities when they encounter inhospitable environmental conditions: to run away or to adapt. As plants have no legs, they therefore need to adapt rapidly to unstable environmental conditions. A plant is hugely flexible in terms of its shape and one of the things that makes this possible is its cytoskeleton, a scaffold consisting of specialized filaments. A group of researchers at the Karlsruhe Institute of Technology (KIT)…https://www.gesundheitsindustrie-bw.de/en/article/news/how-plants-change-their-shape-researchers-at-kit-investigate-cytoskeletal-processes
Press release - 17/06/2011 Lehner GmbH: Text message from houseplant: "Please water me!" Lehner GmbH Sensor-Systeme has developed a completely new system for monitoring plants. Electrodes attached directly to a plant can detect and report water shortages or pest infestation early on, thus optimizing pesticide use and avoiding unnecessary watering. Lehner GmbH Sensor-Systeme, a medium-sized company from Kirchheim unter Teck, scored a victory with this innovation in the 2011 CyberOne business plan competition.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lehner-gmbh-text-message-from-houseplant-please-water-me
Press release - 17/06/2011 Vetter Invests in Additional Lyophilization Capacity Vetter, a leading specialist in aseptic filling, has installed three additional state-of-the-art lyophilizers at the company’s Ravensburg Vetter South facility, nearly doubling its number of freeze-dryers. Altogether, the site will be able to produce up to 24 million lyophilized units annually. The new equipment increases the number of lyophilizers across all Vetter facilities by 30 percent. https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-invests-in-additional-lyophilization-capacity
Press release - 15/06/2011 immatics’ pivotal Phase III trial with IMA901: First patients with renal cell carcinoma are vaccinated immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company’s lead cancer vaccine for the treatment of renal cell carcinoma (RCC).https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-pivotal-phase-iii-trial-with-ima901-first-patients-with-renal-cell-carcinoma-are-vaccinated
Article - 14/06/2011 Retinitis pigmentosa: a new form of cell death What form of cell death do the photoreceptors of people suffering from retinitis pigmentosa undergo and how can their degeneration be prevented or delayed with pharmaceutical substances? Dr. Paquet-Durand from the Institute for Ophthalmic Research in Tübingen is working to resolve these questions.https://www.gesundheitsindustrie-bw.de/en/article/news/retinitis-pigmentosa-a-new-form-of-cell-death
Press release - 12/06/2011 Interview with Nycomed CEO Hakån Björklund Nycomed CEO Hakån Björklund talks about the sale of his company to its Japanese competitor Takeda. He believes that the two companies are well-matched in strategic terms. Björklund has been CEO (chief executive officer) of Nycomed since 1999.https://www.gesundheitsindustrie-bw.de/en/article/press-release/interview-with-nycomed-ceo-hak-n-bjoerklund
Press release - 09/06/2011 Blood Clotting and Bowel Cancer Risk People whose blood clots more easily than normal are more often affected by cancer. Scientists at the German Cancer Research Center have discovered that a number of variants of clotting factor genes have an influence on bowel cancer risk. They found out that carriers of a particular gene variant of clotting factor V have a bowel cancer risk that is six times higher than people who do not have this gene variant.https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-clotting-and-bowel-cancer-risk
Press release - 08/06/2011 NanoDex Inc. NanoDex is an RD venture company located in Ebina Kanagawa Prefecture JAPAN. The core technology of NanoDex is the synthesis and application of folate-modified cyclodextrins ND1 as artificial cancer antibodies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanodex-inc
Press release - 08/06/2011 Meet & Match Intelligent Implants This year's second Meet & Match took place at the Hilton Hotel in Strasbourg, France on May 20, 2011. About 12 presentations were held by representatives from different companies and universities out of the trinational BioValley: Northwest Switzerland, Alsace in France and South Baden in Germany. This Meet & Match meeting has been a great success thanks to interesting talks and a very attentive audience.https://www.gesundheitsindustrie-bw.de/en/article/press-release/meet-match-intelligent-implants
Press release - 08/06/2011 TagCyx Biotechnologies TagCyx is a research based company located in Yokohama Kanagawa Prefecture. The core technologies of TagCyx are unnatural base pair technologies and nucleic acids stabilization technology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tagcyx-biotechnologies
Article - 06/06/2011 Knowledge transfer depends on the application of learning The ability of scientists from different disciplines to understand each other as well as excellent communication skills play an ever-increasing role in the transfer of knowledge from academic research to industry. Vice president of research at the Konstanz University of Applied Sciences HTWG Professor Gunter Voigt explains how academia and industry work together and also highlights the conditions that are necessary for such cooperations to lead…https://www.gesundheitsindustrie-bw.de/en/article/news/knowledge-transfer-depends-on-the-application-of-learning
Article - 06/06/2011 Review: “DKFZ-ZMBH Alliance Forum on Aging & Cancer” in Heidelberg At the DKFZ-ZMBH Alliance Forum 2011 recently held in Heidelberg internationally leading molecular and cell biologists cancer researchers and epidemiologists presented their latest results on the ageing of cells and organisms and the development of cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/review-dkfz-zmbh-alliance-forum-on-aging-cancer-in-heidelberg
Press release - 01/06/2011 Heidelberg expert to coordinate European network on inherited metabolic disorders A European network for research into rare inherited metabolic disorders will be coordinated by PD Dr. Stefan Kölker, head of the Division of Inherited Metabolic Diseases at the Centre for Paediatric and Adolescent Medicine, University of Heidelberg. The project, which will initially run for three years, has a financial volume of 1.3 million euros. More than 40 partners from 17 European countries are part of the “European registry and network for…https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-expert-to-coordinate-european-network-on-inherited-metabolic-disorders
Article - 30/05/2011 BioRN Innovation Center: Innovation broker for market and society With the establishment of the BioRN Innovation Center in the Rhine-Neckar Life Science Cluster, a professional, specialist and neutral intermediary between science and industry will be available to support the transfer of technologies in all of the cluster’s research institutions. In addition, the BioRN Innovation Center acts as a partner for strategic alliances set up to reinforce the competitiveness of the institutions on the European and…https://www.gesundheitsindustrie-bw.de/en/article/news/biorn-innovation-center-innovation-broker-for-market-and-society
Article - 30/05/2011 Technology Licensing Office (TLB): invention and patent management The Technology Licensing Office TLB works in partnership with science and industry and is continuously coming up with new ways to ensure the economic success of inventions from all the key fields of technology. Dr. Frank Schlotter head of Life Sciences at the Karlsruhe-based TLB provides insights into the work that his office does taking as examples innovations from the fields of regenerative medicine and diagnostics.https://www.gesundheitsindustrie-bw.de/en/article/news/technology-licensing-office-tlb-invention-and-patent-management
Article - 30/05/2011 CorTec GmbH – a bridge between ideas and action Brain machine interfaces that are able to read a paralysed patients desired movement from his or her brain and convert it into actual movement might be available in a few years time if everything goes to plan. CorTec GmbH a spin-off company of the University of Freiburg has a technology platform that is able to measure and interpret a persons brain activity and drive muscles or artificial prostheses.https://www.gesundheitsindustrie-bw.de/en/article/news/cortec-gmbh-a-bridge-between-ideas-and-action
Article - 30/05/2011 From bench to bedside to bench The term translational medicine does not always refer to the concept “from bench to bedside and back”, and indeed is often used to refer to many other, somewhat distant, concepts. However, the new translation centres and translational research consortia do correspond to the original meaning. These new centres and consortia have become effective structures in health research in Germany whose goal is the continuous improvement of the diagnostic and…https://www.gesundheitsindustrie-bw.de/en/article/news/from-bench-to-bedside-to-bench
Dossier - 30/05/2011 Knowledge and technology transfer as a social responsibility Technology transfer that efficiently exploits the intellectual property created by publicly funded research is necessary in order to turn scientific discoveries into successful innovations that improve people’s quality of life and boost the economy. The efforts made to rapidly transfer research results from the laboratory into clinical application for the benefit of patients leads to new strategic partnerships and structures in the field of…https://www.gesundheitsindustrie-bw.de/en/article/dossier/knowledge-and-technology-transfer-as-a-social-responsibility
Press release - 26/05/2011 High Scientific Level at the Second International Workshop about Drug-Drug Interactions The organisation team of the Second International DDI drug-drug interactions Workshop has expressed great satisfaction with the course of the scientific meeting. Thus the DDI Workshop at Marbach Castle is on its way to become an established platform for the annual exchange between experts scientists members of the industry and regulatory bodies regarding DDI affairs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-scientific-level-at-the-second-international-workshop-about-drug-drug-interactions